Back to search

West Virginia University

Economics of breast cancer preventive strategies in a Medicaid program

Abstract

dc:description.abstract

The primary objective of the study was to estimate the long-term benefits and costs of chemopreventive tamoxifen and mammography screening in women who are otherwise healthy but at high risk of developing breast cancer. Three hypothetical cohorts of high-risk women were initiated at age forty. The first cohort consumed chemopreventive tamoxifen and underwent routine mammography screening. The second cohort also consumed chemopreventive tamoxifen but underwent mammography screening at real-world rates. The third cohort (control cohort) did not consume chemopreventive tamoxifen and underwent mammography screening at real-world rates. The study also assessed the proportion of women in the West Virginia Medicaid Program (WVMP) who were healthy but at a high risk of developing breast cancer. Secondary objectives of the study involved determining breast cancer knowledge, utilization of breast cancer preventive strategies, and willingness to consume chemopreventive tamoxifen. Chemopreventive tamoxifen coupled with routine mammography screening resulted in an incremental life expectancy gain of 0.122 years at an incremental cost of {dollar}5,969.70 resulting in an incremental cost effectiveness ratio (ICER) of {dollar}48,931.80 per life year gained (3% discount rate) as compared to control cohort. Chemopreventive tamoxifen coupled with mammography screening at real-world rates resulted in an incremental life expectancy gain of 0.076 years at an incremental cost of {dollar}4,916.84 resulting in an incremental cost effectiveness ratio (ICER) of {dollar}64,695.20 per life year gained (3% discount rate) as compared to control cohort. Sensitivity analysis indicated robustness of results over a wide rage of assumptions. About half of the surveyed population was at a high risk of developing breast cancer and thus eligible to receive chemopreventive tamoxifen. However, only about 17% respondents indicated their inclination towards consuming chemopreventive tamoxifen. A low but significant correlation was observed between the respondent's perceived risk and real risk indicating the need for increasing breast cancer awareness. Respondent's actual risk of developing breast cancer did not appear to have any relationship with willingness to consume chemopreventive tamoxifen. In summary, chemopreventive tamoxifen plus mammography screening in high-risk women is a cost-effective strategy. However, at present, very few of these high-risk women may actually utilize chemoprevention.

Degree

thesis:*
Name thesis:degree_name
PhD
Level thesis:degree_level
Dissertation
Discipline thesis:degree_discipline
Pharmaceutical Sciences

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Borker, Rohit D.

Subjects

dc:subject × 3

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
West Virginia University
Base URL
researchrepository.wvu.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Borker, Rohit D.. Economics of breast cancer preventive strategies in a Medicaid program. Dissertation thesis, https://doi.org/10.33915/etd.1842